canaccord remote access

Cloud DX and Prizm Media to Provide Patients with Direct Access to Remote Patient Monitoring

Patient-First Program Opens Direct Access to thousands of US Patients

  • Cloud DX partners with Prizm Media on a new ‘patient-first' program to improve patient access to RPM in a uniquely scalable way.
  • The contract gives Cloud DX and physician partners immediate access to thousands of patients with chronic illnesses in initial rollout states (Illinois, New Jersey, and Florida) through Prizm's extensive patient database.
  • On launch, Cloud DX plans to connect up to 2,000 eligible US seniors to its Connected HealthTM platform. Once fully deployed this equates to approximately US$1.4 million (CAD $1.8 million) per year in revenue at an expected gross margin of 75%.
  • By pre-qualifying and educating patients, Cloud DX plans to reduce the current timeline between signing an RPM contract with a provider and enrolling patients.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce a new program in the United States that aims to identify, qualify, and enroll selected patients with chronic conditions in Illinois, New Jersey, and Florida for reimbursed RPM programs. Other States may also be targeted

"Our mission is to make healthcare better for everyone, and that includes accessibility. Many patients can benefit from RPM, but often due to implementation challenges, these individuals are unable to access remote monitoring to manage their disease symptoms and progression," says Robert Kaul, CEO of Cloud DX.

"With this program, we're giving power back to the patient. We intend to dramatically expedite access to RPM services for patients with a high degree of need by working with a highly compliant firm like Prizm, that has vast experience in identifying and engaging those most likely to benefit. They can opt-in on their own, with their personal physician, or through a Cloud DX partner physician. Streamlined access to RPM means we'll be able to more quickly connect patients to healthcare services, relieving some of the burden from an overwhelmed healthcare system."

Prizm Media specializes in compliant omnichannel marketing for healthcare firms and has relationships with over 1,000,000 US patients diagnosed with one or more chronic conditions. Cloud DX and Prizm will launch a marketing program that will aim to identify up to 2,000 patients with late-stage COPD in States with large senior populations. Patients will be onboarded to a Connected HealthTM RPM plan, optimized to work for them, deployed by their primary care provider or a Cloud DX partner.

When a patient enrolls in an RPM program deployed by Cloud DX, the Company earns a per-patient-per-month fee up to US$60/month, or US$720/year. Under a contract executed on September 15, 2021, Cloud DX will pay Prizm an initial US$30,000 per month for three months in marketing fees with option to extend and scale up. No minimum or maximum number of patients is specified under the Safe Harbor and fair market value arrangement. Prizm has specialized in outreach to US patients with chronic illness since 2001.

This new patient-first approach augments Cloud DX's previously announced programs marketing Connected Health services directly to clinics and hospitals.

Join CEO, Robert Kaul in October for an in-depth look at Cloud DX's future revenue outlook. The next monthly investor's update, ‘Gearing Up Revenue', will be held October 12, at 12:00 pm EDT. Registration is now live.

About Prizm Media

Prizm Media was founded in 2001 with the vision of making an impact in healthcare through digital media & technology using a compliance first approach They have connected millions of people with chronic conditions across North America to hundreds of vetted healthcare organizations . Their services have enabled healthcare firms to grow revenues, create jobs and reduce environmental impacts by improving patient-to-provider workflows, while also improving patient outcomes and delivery of care. Prizm Media an EY Entrepreneur of the Year Award Finalist, Profit 500 recipient and was recently recognized as one of the BC500 by Business in Vancouver in the Health Tech category.

About Cloud DX

Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place, and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers."

Cloud DX Investor Site

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

# # #

Social Links
Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@clouddcx.com

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE:Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/664378/Cloud-DX-and-Prizm-Media-to-Provide-Patients-with-Direct-Access-to-Remote-Patient-Monitoring

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×